Inventor · disambiguated record
Vafa Shahabi
Also filed as: SHAHABI VAFA
7 granted patents·11 pending applications·93 citations·filing 2005–2019
87Inventor score
Top patents by PatentIndex Score
18 records- 0193US9549973B2Compositions and methods comprising KLK3 or FOLH1 antigenUNIV PENNSYLVANIA·Filed 2014·Granted Jan 24, 2017·16 cites·31 claims
- 0291US9012141B2Compositions and methods comprising KLK3 of FOLH1 antigenPATERSON YVONNE·Filed 2007·Granted Apr 21, 2015·14 cites·15 claims
- 0390US11446369B2Compositions and methods comprising KLK3 or FOLH1 antigenADVAXIS INC·Filed 2019·Granted Sep 20, 2022·3 cites·16 claims
- 0490US9650639B2Dual delivery system for heterologous antigensADVAXIS INC·Filed 2014·Granted May 16, 2017·11 cites·18 claims
- 0590US9017660B2Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumorsSHAHABI VAFA·Filed 2011·Granted Apr 28, 2015·22 cites·61 claims
- 0688US9644212B2Dual delivery system for heterologous antigensADVAXIS INC·Filed 2014·Granted May 9, 2017·11 cites·10 claims
- 0787US9084747B2Compositions and methods for prevention of escape mutation in the treatment of HER2/NEU over-expressing tumorsSHAHABI VAFA·Filed 2010·Granted Jul 21, 2015·16 cites·25 claims
- 0861US2015366955A9Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumorsADVAXIS INC·Filed 2014·Application pending·0 cites
- 0961US2014234370A1Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumorsADVAXIS INC·Filed 2014·Application pending·0 cites
- 1058US2011129499A1Dual delivery system for heterologous antigensMACIAG PAULO·Filed 2009·Application pending·0 cites
- 1156US2017100469A1Compositions and methods comprising klk3 or folh1 antigenUNIV PENNSYLVANIA·Filed 2016·Application pending·0 cites
- 1250US2015297702A1Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumorsADVAXIS INC·Filed 2015·Application pending·0 cites
- 1347US2016361401A1Compositions and methods for the treatment of her2/neu over-expressing tumorsADVAXIS INC·Filed 2015·Application pending·0 cites
- 1444US2015110779A1Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathwayBRISTOL MYERS SQUIBB CO·Filed 2013·Application pending·0 cites
- 1544US2009069256A1Enhancing protein expressionSMITH LARRY R·Filed 2005·Application pending·0 cites
- 1641US2015299804A1Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agentBRISTOL MYERS SQUIBB CO·Filed 2013·Application pending·0 cites
- 1738US2015118244A1Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patientsBRISTOL MYERS SQUIBB CO·Filed 2013·Application pending·0 cites
- 1838US2011223187A1Live listeria-based vaccines for central nervous system therapySHAHABI VAFA·Filed 2011·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →